Guardant Health (GH)
(Real Time Quote from BATS)
$29.82 USD
-0.24 (-0.80%)
Updated Jun 11, 2024 12:30 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GH 29.82 -0.24(-0.80%)
Will GH be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for GH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GH
Guardant Health (GH) Recently Broke Out Above the 200-Day Moving Average
Stock Market News for May 13, 2024
GH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
Other News for GH
Guardant: Double-Digit Sales Projections Come At A Cost
Guardant Health Poised for Growth: FDA Approval, Strategic Financial Management, and Market Penetration Fuel Buy Rating
Guardant Health Inc's Meteoric Rise: Unpacking the 51% Surge in Just 3 Months
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
Guardant Health price target raised by $8 at Canaccord, here's why